血管免疫母细胞性T细胞淋巴瘤的病因及治疗研究进展

Progress on etiology and treatment of angioimmunoblastic T-cell lymphoma

血管免疫母细胞性T细胞淋巴瘤(angioimmunoblastic T-cell lymphoma,AITL)是淋巴瘤的一种罕见亚型,但却是T细胞淋巴瘤常见的类型之一,约占外周血T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)的15%~20%,具有独特的临床表现和病理学特点。随着科学技术的提高,近年来对血管免疫母细胞性T细胞淋巴瘤的病因及发病机制的认识有了进一步的深入,也有越来越多新的治疗方案被应用于临床。本文就本病的病因及治疗进展进行综述。

Angioimmunoblastic T-cell lymphoma(AITL)is a rare subtype of lymphoma but one of the most common types of T-cell lymphoma,representing about 15%~20%of cases of peripheral T-cell lymphoma(PTCL).It is characterized by a unique clinical presentation and distinct pathologic and molecular features.With the progress of technology,the research on the pathogenesis of AITL has been further deepened,and more and more new therapeutic methods have been applied in clinical practice.This chapter reviews the progress on etiology and treatment of angioimmunoblastic T-cell lymphoma.